The joint diabetes venture between pharmaceutical companies AstraZeneca and Bristol-Meyers Squibb has come to an end following AstraZeneca’s takeover of its former partner’s interest in the companies’ diabetes alliance.
The Anglo-Swedish drugmaker announced on Monday that it had completed its acquisition of Bristol-Myers Squibb’s stake in their joint diabetes business, giving it full ownership of the intellectual property and global rights for the development, manufacture and commercialisation of a portfolio of drug treatments for adult diabetics.
The portfolio includes Onglyza (saxagliptin), Komboglyze (saxagliptin and metformin), Forxiga (dapagliflozin), Xigduo (dapagliflozin and metformin), as well as Byetta (exenatide), Bydureon (extended-release exenatide) and Symlin (pramlintide), which were purchased through last year’s takeover of Amylin.
Upon completion of the purchase, AstraZeneca paid Bristol-Meyers an initial $2.7bn (£1.7bn) and has also agreed to pay the American pharmaceutical a further $1.4bn (£860m) in stages payments up until 2025.
Announcing the acquisitio, AstraZeneca CEO Pascal Soriot, said: “I extend a warm welcome to our new colleagues and I’m delighted with the speed at which we’ve completed the acquisition which reinforces our long-term commitment to patients with diabetes.
“Under a single leadership, we will maximise the potential of our innovative portfolio of non-insulin anti-diabetic medicines, bringing fresh momentum to our growth ambitions for this franchise.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…